Respiratory Syncytial Virus Market Growth, Trends & Forecast 2025 | Top key players - Sanofi, GSK plc, Pfizer.

The Global Respiratory Syncytial Virus (RSV) Market reached USD 1.2 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 2.4 billion by 2030. The market is expected to exhibit a CAGR of 10.2% during the forecast period (2024-2031).

Respiratory Syncytial Virus Market report, published by DataM Intelligence, delivers detailed insights and analysis on major market trends, growth prospects, and emerging challenges. With a strong focus on providing actionable intelligence, DataM Intelligence enables businesses to make well-informed decisions and maintain a competitive edge. By blending both qualitative and quantitative research approaches, the company offers thorough reports that support clients in navigating complex market environments, driving strategic expansion, and capitalizing on new opportunities in today's rapidly evolving global landscape.

The Respiratory Syncytial Virus (RSV) Market focuses on the prevention, treatment, and management of RSV infections, which commonly affect infants, elderly adults, and those with compromised immune systems. Key market segments include vaccines, antiviral therapies, and diagnostics. Growing awareness, advancements in medical research, and increased funding for vaccine development are driving the market's expansion.

Request a Free Sample PDF of This Report (Corporate Email IDs Receive Priority Service): https://datamintelligence.com/download-sample/respiratory-syncytial-virus-market?sz

Market opportunities and Growth Drivers:

Increasing Prevalence of RSV is a Key Factor Helping Market Expansion

Respiratory Syncytial Virus (RSV) is a common virus that primarily impacts young children, causing mild to severe respiratory issues. RSV infections are most prevalent during the autumn, winter, and early spring months. It's a leading cause of lower respiratory tract infections in infants and young children, often leading to conditions like bronchiolitis and pneumonia. Although it mainly affects younger children, RSV can also cause complications in older adults and individuals with weakened immune systems.

For example, the National Institute of Allergy and Infectious Diseases (NIAID) states that RSV is the top cause of bronchiolitis in infants under one year old in the U.S., resulting in about 58,000 hospitalizations annually. Additionally, RSV is responsible for around 14,000 deaths each year among individuals over the age of 65 in the U.S. On a global scale, RSV affects approximately 64 million people and causes 160,000 deaths each year. These alarming statistics are key factors driving the growth of the RSV treatment market.

Respiratory Syncytial Virus Market Recent Development:

On May 3, 2023, GSK plc achieved a major breakthrough when the U.S. Food and Drug Administration (FDA) approved Arexvy, an adjuvanted respiratory syncytial virus (RSV) vaccine, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 and older. This marks the world's first licensed RSV vaccine specifically for older individuals.

On November 4, 2022, Sanofi and AstraZeneca's Beyfortus (nirsevimab) received authorization from the European Commission. This long-acting medication was approved for the prevention of respiratory illnesses caused by RSV in newborns, offering a crucial option to protect infants from this common and highly contagious virus.

List of the Key Players in the Respiratory Syncytial Virus Market:

Sanofi, GSK plc, Pfizer, AstraZeneca, AbbVie, Bausch Health Companies, Bavarian Nordic, Merck & Co, Moderna, Inc., and mAbxience, among others.

Research Process:

Both primary and secondary data sources have been used in the global Respiratory Syncytial Virus Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/respiratory-syncytial-virus-market

Segment Covered in the Respiratory Syncytial Virus Market:

By Drug Type: Ribavirin, Nirsevimab, Virazole, Palivizumab, Riba Tab, Others.

By Dosage Form: Oral, Injectable, Inhaler, Others.

By Treatment Type: Immune prophylaxis, Supportive care, Antiviral Medications.

By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy.

Regional Analysis for Respiratory Syncytial Virus Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

People Also Ask:

Most Frequently Asked Questions in the Respiratory Syncytial Virus Market Research Industry:

➠ What are the global figures for sales, production, consumption, imports, and exports in the Respiratory Syncytial Virus market?

➠ Who are the top manufacturers in the global Respiratory Syncytial Virus industry, and what is their current status in terms of production capacity, output, sales performance, pricing structure, cost analysis, profit margins, and overall revenue?

➠ What key opportunities are available for vendors in the Respiratory Syncytial Virus market, and what challenges are they likely to encounter?

➠ Which application areas, end-user segments, or product types are projected to experience significant growth, and how is the market share distributed among them?

➠ What are the major drivers and barriers influencing the growth trajectory of the Respiratory Syncytial Virus market?

➠ What are the primary sales, marketing, and distribution strategies used across the global Respiratory Syncytial Virus industry landscape?

Browse More Reports: https://www.datamintelligence.com/research-report/respiratory-syncytial-virus-market

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.